Enzalutamide reduces skeletal-related events in men with advanced castration-resistant prostate cancer
the ONA take:
According to a new study published in the journal Lancet Oncology, enzalutamide was found to decrease the risk of skeletal-related events, including radiotherapy to the bone and spinal cord compression, in men with metastatic castration-resistant prostate cancer (mCRPC). In addition, enzalutamide lowered pain and increased quality of life.
In the phase 3 AFFIRM study, patients with mCRPC whose disease progressed on or after docetaxel either took enzalutamide, an androgen receptor, by mouth once daily or placebo. Researchers found that enzalutamide decreased the risk of skeletal-related events by 31% compared with placebo (P=0.0001), and the duration to first skeletal-related event was 16.7 months for patients who took enzalutamide versus 13.3 months for those who took placebo (P=0.0001).
Furthermore, enzalutamide decreased pain severity (P<0.0001) and risk of pain progression (P=0.0018). Patients on enzalutamide experienced health-related quality of life (HRQoL) deterioration after 9.0 months, while those on placebo had HRQoL deterioration in 3.7 months (P<0.0001).
Xtandi (enzalutamide) was initially approved by the U.S. Food and Drug Administration (FDA) in 2012, and the FDA recently approved enzalutamide as first-line therapy for men with mCRPC.
Enzalutamide was found to decrease the risk of skeletal-related events in mCRPC.
Enzalutamide (XTANDI™) reduces the risk of skeletal-related events compared with placebo, as well as reducing pain and increasing quality of life in men with metastatic castration-resistant prostate cancer (mCRPC) according to new results from the AFFIRM study published in Lancet Oncology.
Bone is the most common site of spread in prostate cancer, accounting for about 90% of metastases, resulting in some of the most painful and functionally compromising complications of the disease.
Professor Johann De Bono, Professor of Experimental Cancer Medicine at The Institute of Cancer Research London, and Head of the Drug Development Unit at The Royal Marsden NHS Foundation Trust, comments: "These quality of life data endorse the fact that enzalutamide is a major advance in the treatment of prostate cancer."
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|